The 2026-2027 seasonal flu and Covid-19 vaccination campaign will officially begin on October 13, as announced by the General Directorate of Health (DGS). Eligible individuals will be able to receive both vaccines during the same session, at two distinct injection sites. This follows the same approach as previous years, with no major changes in how the vaccines are administered. The flu vaccination recommendations target specific groups, including healthcare professionals and others who have regular and prolonged contact with people at high risk of severe flu. People at risk of developing a severe form of these diseases include those aged 65 and older, pregnant women, immunocompromised individuals, residents of social and medical-social establishments, people with certain health conditions, and those with obesity and a body mass index (BMI) of 40 kg/m2 or higher. Additionally, people in regular contact with those at risk are also included in the recommendations. This year marks the first year of a specific influenza vaccination requirement for healthcare workers, as indicated in the authorities' communication. However, the full regulatory framework making this requirement enforceable is expected to be completed by the end of the first quarter of 2027. This timeline should allow for maximizing vaccine coverage across the population. Regarding vaccination access, doctors, pharmacists, nurses, midwives, pharmacy technicians, and other third-cycle medical and pharmacy students can prescribe and/or administer flu and Covid-19 vaccines to targeted or non-targeted individuals, under certain conditions. For all individuals identified as "at risk" by the Social Security, vaccination is fully covered during the campaign period. Eligible individuals receive a voucher to access the vaccines. For others, a prescription is now mandatory, and there is no coverage for the procedure. Five different vaccines are available against seasonal flu: Efluelda, Fluad, Flucelvax, Influvac, and Vaxigrip. For people aged 65 and older, the Efluelda (high dose) and Fluad (with adjuvant) vaccines are recommended preferentially. Regarding Covid-19, two vaccines are available: one for adults and children aged 12 and older (Comirnaty XFG adult), and another for pediatric use (Comirnaty XFG pediatric, for children aged 6 months to 11 years). Winter is not yet here, but viruses are already causing damage in France. According to the report from Santé publique France released last week, suspicions of Covid-19 and influenza are already significant. Regarding influenza and influenza-like symptoms, there has been a 32% increase in consultations compared to the previous week, with 115 additional emergency room visits, at levels "slightly higher than those of previous years." For Covid-19, there is a 16% increase in suspicions (+25 visits) among children and a 67% increase (+204 visits) among adults. On average, the peak of the epidemic occurs much later in the year, according to the analysis of data from previous seasons.